Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7251 results

Sort By:

Biomarkers of CASH

Study ID: NCT04467489
Start Date: 2020-05-22
End Date: 2026-06-30
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

1040

Intervention / Treatment

observational

Sponsor

University of Chicago

Source: clinicaltrials.gov

Share:
Add to list

Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?

Study ID: NCT03261544
Start Date: 2017-11-10
End Date: 2028-11
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

50

Intervention / Treatment

Proximal Femur Replacement

Sponsor

Duke University

Source: clinicaltrials.gov

Share:
Add to list

ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Study ID: NCT06351644
Start Date: 2024-09-19
End Date: 2028-06-05
Study Type

Interventional

Study Phase

Phase2

No. of Participants

36

Intervention / Treatment

ON 123300

Dexamethasone

Sponsor

Adriana Rossi

Source: clinicaltrials.gov

Share:
Add to list

The Ohio State University (OSU) SCREEN Community Program

Study ID: NCT06666192
Start Date: 2024-03-12
End Date: 2029-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

2067

Intervention / Treatment

Cancer Screening

Discussion

Educational Activity

Educational Intervention

Focus Group

Health Care Delivery

Health Promotion

Health Promotion and Education

Health Promotion and Education

Health Promotion and Education

Health Risk Assessment

Implementation

Informational Intervention

Internet-Based Intervention

Interview

Outreach

Patient Navigation

Survey Administration

Sponsor

Ohio State University Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

Study ID: NCT01555892
Start Date: 2013-01-14
End Date: 2026-07-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

136

Intervention / Treatment

EBV-specific T cells: A

EBV-specific T cells: B

Sponsor

Baylor College of Medicine

Source: clinicaltrials.gov

Share:
Add to list

Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

Study ID: NCT07010692
Start Date: 2025-05-16
End Date: 2030-06
Study Type

Interventional

Study Phase

Phase2

No. of Participants

100

Intervention / Treatment

Tirbanibulin ointment 1%

non-ablative fractional laser

Sponsor

Bruce Robinson, MD

Source: clinicaltrials.gov

Share:
Add to list

Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers

Study ID: NCT05823740
Start Date: 2023-05-01
End Date: 2026-06-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

30

Intervention / Treatment

Bioelectrical impedance Analysis (BIA)

D3-Creatine Dilution (D3Cr)

6-Minute Walk Test (6MWT)

Timed Up and Go (TUG)

30-second Sit-to-Stand (STS)

Hand Grip Strength (GS)

PBTL p16 expression

CT, MR and PET Imaging

Sponsor

UNC Lineberger Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Insomnia in Patients With Metastatic Lung Cancer

Study ID: NCT06472804
Start Date: 2019-06-19
End Date: 2026-06
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

60

Intervention / Treatment

Non-Interventional Study

Sponsor

Mayo Clinic

Source: clinicaltrials.gov

Share:
Add to list

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Study ID: NCT06382168
Start Date: 2024-06-12
End Date: 2025-06-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

39

Intervention / Treatment

DFP-10917

Venetoclax

Sponsor

Delta-Fly Pharma, Inc.

Source: clinicaltrials.gov

Share:
Add to list

A Phase 3B Study to Evaluate Bone Mineral Density with Long-Term Use of Relugolix Combination Tablet in Women with Uterine Fibroids or Endometriosis

Study ID: NCT05862272
Start Date: 2023-08-14
End Date: 2030-09
Study Type

Interventional

Study Phase

Phase3

No. of Participants

1000

Intervention / Treatment

Relugolix Combination Tablet

Sponsor

Sumitomo Pharma Switzerland GmbH

Source: clinicaltrials.gov

Share:
Add to list